{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:11:39Z","timestamp":1769155899323,"version":"3.49.0"},"posted":{"date-parts":[[2025,3,11]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":51,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,3,11]]},"abstract":"<jats:title>Summary<\/jats:title>\n                <jats:p>\n                  Artemisinin-based combination therapies are the frontline drugs for the treatment of malaria infections but, for\n                  <jats:italic>Plasmodium falciparum,<\/jats:italic>\n                  the efficacy of artemisinin is threatened by the spread of resistance\n                  <jats:italic>. P. vivax<\/jats:italic>\n                  is the second most common cause of human malaria but we have little information on its susceptibility to artemisinin due to the lack of\n                  <jats:italic>in vitro<\/jats:italic>\n                  cultures. Here, we analyze 161\n                  <jats:italic>P. vivax<\/jats:italic>\n                  infections from Cambodian patients treated with 2 mg\/kg\/day of artesunate for seven days. All infections were successfully cleared by day 3. However, one third of the infections displayed a slow clearance after treatment, with nine infections (5.7%) with a parasite clearance time greater than 5 hours, meeting the WHO definition of artemisinin resistance. We observed no significant association between slow clearance and either patient- or infection characteristics (including stage composition). We used RNA-seq to characterize the gene expression of parasites from 15 fast- and 16 slow-clearing infections at baseline and 1, 2 and 4 hours after treatment. While fast-clearing parasites showed significant changes in gene expression immediately upon treatment, slow-clearing parasites displayed a significantly delayed gene expression response, with a downregulation of many genes associated with hemoglobin endocytosis and digestion. Overall, our results indicate that some Cambodian\n                  <jats:italic>P. vivax<\/jats:italic>\n                  parasites clear slowly after artesunate treatment, possibly due to a downregulation of hemoglobin metabolism that may reduce the efficiency of the artesunate.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>Research in context<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Evidence before this study<\/jats:title>\n                    <jats:p>\n                      The WHO treatment guidelines recommend artemisinin-combination therapy (ACT) for treatment of blood-stage infections caused by\n                      <jats:italic>Plasmodium vivax<\/jats:italic>\n                      in all areas (with chloroquine recommended only in areas where\n                      <jats:italic>P. vivax<\/jats:italic>\n                      are still chloroquine-sensitive). In\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      , partial resistance to artemisinin derivatives is defined\n                      <jats:italic>in vivo<\/jats:italic>\n                      as either detected parasitemia on day 3 post treatment or as a half-life of the parasite clearance slope of \u2265 5 hours. We searched Pubmed for studies containing the terms \"vivax\" AND \"clearance\" AND (\"artesunate\" OR \"dihydroartemisinin\" OR \"artemether\" OR \"artemisinin\") published between 1990 and February 2025, with no language restrictions. Our search retrieved 102 studies for which title and abstracts were screened to identify 21 studies reporting outcomes of\n                      <jats:italic>P. vivax<\/jats:italic>\n                      treatment with an artemisinin derivative. While all these studies concluded that artemisinin derivatives provided rapid clearance of\n                      <jats:italic>P. vivax<\/jats:italic>\n                      parasites, two studies reported a low frequency of day 3 positivity following artesunate-amodiaquine treatment (2.6% in Brazil) or dihydroartemisinin-piperaquine (0.6% in Indonesia). No study reported clearance slope half-life \u2265 5 hours.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Added value of this study<\/jats:title>\n                    <jats:p>\n                      This study used a cohort of Cambodian patients infected by\n                      <jats:italic>P. vivax<\/jats:italic>\n                      to rigorously examine the efficacy of artesunate monotherapy at clearing blood stage infections. Our study showed significant variations in clearance rates among infections, with 5.7% of the infections with a clearance slope half-life \u2265 5 hours, meeting the criteria for artemisinin partial resistance used for\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      . Variations in clearance rate upon artesunate treatment were not associated with patient or infection characteristics. Gene expression analyses revealed that the slow-clearing parasites down-regulated upon treatment many genes involved in hemoglobin endocytosis and digestion, possibly resulting in a lesser activation of artesunate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications of all the available evidence<\/jats:title>\n                    <jats:p>\n                      Our results confirm that 2 mg\/kg of artesunate per day for seven days is effective at clearing\n                      <jats:italic>P. vivax<\/jats:italic>\n                      blood stage infections. However, a subset of the\n                      <jats:italic>P. vivax<\/jats:italic>\n                      parasites displayed a slow clearance following artesunate treatment meeting artemisinin partial resistance definition in\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      . Gene expression analyses suggest that metabolic variations may underlie slow clearance. Increased monitoring of treatment efficacy and drug resistance in\n                      <jats:italic>P. vivax<\/jats:italic>\n                      is therefore recommended.\n                    <\/jats:p>\n                  <\/jats:sec>\n                <\/jats:sec>","DOI":"10.1101\/2025.03.09.25323469","type":"posted-content","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T12:53:12Z","timestamp":1741870392000},"source":"Crossref","is-referenced-by-count":2,"title":["Cambodian\n                  <i>Plasmodium vivax<\/i>\n                  parasites with reduced hemoglobin digestion display delayed clearance upon artesunate treatment"],"prefix":"10.64898","author":[{"given":"Kieran","family":"Tebben","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virak","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dynang","family":"Seng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baura","family":"Tat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel Brice","family":"Feufack Donfack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Orban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rominea","family":"Yeat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sitha","family":"Sin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimol","family":"Khim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Flamand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecile","family":"Sommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dysoley","family":"Lek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Serre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Popovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025032002575306000_2025.03.09.25323469v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808859"},{"key":"2025032002575306000_2025.03.09.25323469v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0805011"},{"key":"2025032002575306000_2025.03.09.25323469v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314981"},{"key":"2025032002575306000_2025.03.09.25323469v1.4","doi-asserted-by":"crossref","unstructured":"Rosenthal, P.J. , et al., The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect Dis, 2024.","DOI":"10.1016\/S1473-3099(24)00141-5"},{"key":"2025032002575306000_2025.03.09.25323469v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00142-0"},{"key":"2025032002575306000_2025.03.09.25323469v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101746"},{"key":"2025032002575306000_2025.03.09.25323469v1.7","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix334"},{"key":"2025032002575306000_2025.03.09.25323469v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00487-9"},{"key":"2025032002575306000_2025.03.09.25323469v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30409-1"},{"key":"2025032002575306000_2025.03.09.25323469v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2006.07.011"},{"key":"2025032002575306000_2025.03.09.25323469v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2016.05.010"},{"issue":"1","key":"2025032002575306000_2025.03.09.25323469v1.12","first-page":"274","article-title":"Artemisinin resistance in the malaria parasite","volume":"5","year":"2022","journal-title":"Plasmodium falciparum, originates from its initial transcriptional response. Commun Biol"},{"key":"2025032002575306000_2025.03.09.25323469v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06221-1"},{"key":"2025032002575306000_2025.03.09.25323469v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2022.102193"},{"key":"2025032002575306000_2025.03.09.25323469v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7519(02)00194-7"},{"key":"2025032002575306000_2025.03.09.25323469v1.16","unstructured":"World Health Organization, World malaria report 2023. 2023, World Health Organization: Geneva."},{"key":"2025032002575306000_2025.03.09.25323469v1.17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy484"},{"key":"2025032002575306000_2025.03.09.25323469v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2020.12.001"},{"key":"2025032002575306000_2025.03.09.25323469v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099"},{"key":"2025032002575306000_2025.03.09.25323469v1.20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.12688\/wellcomeopenres.9876.1","article-title":"A new Plasmodium vivax reference sequence with improved assembly of the subtelomeres reveals an abundance of pir genes","volume":"1","year":"2016","journal-title":"Wellcome Open Res"},{"key":"2025032002575306000_2025.03.09.25323469v1.21","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1923"},{"key":"2025032002575306000_2025.03.09.25323469v1.22","unstructured":"Van der Auwera GA . and O.C. BD., Genomics in the Cloud: Using Docker, GATK, and WDL in Terra. 1 ed. 2020: O\u2019Reilly Media."},{"key":"2025032002575306000_2025.03.09.25323469v1.23","unstructured":"Lee, S. and M. Bahlo , moimix: an R package for assessing clonality in high-througput sequencing data. 2016."},{"key":"2025032002575306000_2025.03.09.25323469v1.24","doi-asserted-by":"crossref","unstructured":"Chan, E.R. , et al., Whole Genome Sequencing of Field Isolates Provides Robust Characterization of Genetic Diversity in Plasmodium vivax, in PLoS Neglected Tropical Diseases. 2012.","DOI":"10.1371\/journal.pntd.0001811"},{"key":"2025032002575306000_2025.03.09.25323469v1.25","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp352"},{"key":"2025032002575306000_2025.03.09.25323469v1.26","doi-asserted-by":"publisher","DOI":"10.1093\/MOLBEV\/MSAB120"},{"key":"2025032002575306000_2025.03.09.25323469v1.27","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btr509"},{"key":"2025032002575306000_2025.03.09.25323469v1.28","unstructured":"Haas, B."},{"key":"2025032002575306000_2025.03.09.25323469v1.29","unstructured":"Maddison, W.P. and D.R. Maddison , Mesquite: A modular system for evolutionary analysis. Version 3.81. 2023."},{"key":"2025032002575306000_2025.03.09.25323469v1.30","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3317"},{"key":"2025032002575306000_2025.03.09.25323469v1.31","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt656"},{"key":"2025032002575306000_2025.03.09.25323469v1.32","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp616"},{"issue":"1","key":"2025032002575306000_2025.03.09.25323469v1.33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","year":"1995","journal-title":"Journal of the Royal Statistical Society. Serie B"},{"key":"2025032002575306000_2025.03.09.25323469v1.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0114-2"},{"key":"2025032002575306000_2025.03.09.25323469v1.35","doi-asserted-by":"publisher","DOI":"10.1128\/msystems.00258-22"},{"key":"2025032002575306000_2025.03.09.25323469v1.36","doi-asserted-by":"crossref","unstructured":"Eng, V. , et al., High versus low dose of 14 days treatment of primaquine in Plasmodium vivax infected patients in Cambodia: a randomised open-label efficacy study. medRxiv, 2025: p. 2025.01.01.25319862.","DOI":"10.1101\/2025.01.01.25319862"},{"key":"2025032002575306000_2025.03.09.25323469v1.37","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-339"},{"key":"2025032002575306000_2025.03.09.25323469v1.38","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-015-2040-0"},{"key":"2025032002575306000_2025.03.09.25323469v1.39","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-3-23"},{"issue":"7","key":"2025032002575306000_2025.03.09.25323469v1.40","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1021\/acsinfecdis.9b00527","article-title":"Plasmodium falciparum Artemisinin Resistance: The Effect of Heme, Protein Damage, and Parasite Cell Stress Response","volume":"6","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2025032002575306000_2025.03.09.25323469v1.41","doi-asserted-by":"crossref","unstructured":"Ullah, I. , et al., Artemisinin resistance mutations in Pfcoronin impede hemoglobin uptake. bioRxiv, 2024.","DOI":"10.1101\/2023.12.22.572193"},{"key":"2025032002575306000_2025.03.09.25323469v1.42","doi-asserted-by":"publisher","DOI":"10.1038\/nature12876"},{"key":"2025032002575306000_2025.03.09.25323469v1.43","doi-asserted-by":"publisher","DOI":"10.1093\/NAR\/GKAB683"},{"key":"2025032002575306000_2025.03.09.25323469v1.44","doi-asserted-by":"crossref","unstructured":"Portugaliza, H.P. , et al., Artemisinin exposure at the ring or trophozoite stage impacts Plasmodium falciparum sexual conversion differently. Elife, 2020. 9.","DOI":"10.7554\/eLife.60058"},{"key":"2025032002575306000_2025.03.09.25323469v1.45","doi-asserted-by":"crossref","first-page":"104198","DOI":"10.1016\/j.ebiom.2022.104198","article-title":"Plasmodium falciparum sexual conversion rates can be affected by artemisinin-based treatment in naturally infected malaria patients","volume":"83","year":"2022","journal-title":"EBioMedicine"},{"key":"2025032002575306000_2025.03.09.25323469v1.46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001811"},{"key":"2025032002575306000_2025.03.09.25323469v1.47","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3599"},{"key":"2025032002575306000_2025.03.09.25323469v1.48","doi-asserted-by":"crossref","unstructured":"Popovici, J. , et al., Genomic Analyses Reveal the Common Occurrence and Complexity of Plasmodium vivax Relapses in Cambodia. mBio, 2018. 9(1).","DOI":"10.1128\/mBio.01888-17"},{"key":"2025032002575306000_2025.03.09.25323469v1.49","doi-asserted-by":"publisher","DOI":"10.1086\/512241"},{"key":"2025032002575306000_2025.03.09.25323469v1.50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039645"},{"issue":"7","key":"2025032002575306000_2025.03.09.25323469v1.51","doi-asserted-by":"crossref","first-page":"e0010648","DOI":"10.1371\/journal.pntd.0010648","article-title":"Hypnozoite depletion in successive Plasmodium vivax relapses","volume":"16","year":"2022","journal-title":"PLoS Negl Trop Dis"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.03.09.25323469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:30:22Z","timestamp":1768509022000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.03.09.25323469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1101\/2025.03.09.25323469","relation":{},"subject":[],"published":{"date-parts":[[2025,3,11]]},"subtype":"preprint"}}